Extensive cystic fibrosis transmembrane conductance regulator gene analysis by denaturing gradient gel electrophoresis, denaturing high-performance liquid chromatography, and DNA sequencing ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...

The cystic fibrosis transmembrane conductance regulator has been studied for years but the new efforts have yielded important insights.

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Patients naïve to cystic fibrosis transmembrane conductance regulator modulators had comparable improvements to patients with prior exposure.

A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

Cystic fibrosis (CF) is a genetic condition that affects the lungs, pancreas and other organs, caused by variations on the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...

Here's what cystic fibrosis is, what causes it and how it's usually treated once it has been diagnosed. Start the day smarter. Get all the news you need in your inbox each morning. What is ...

Individuals with cystic fibrosis or CFTR gene variants have a 3-fold higher risk of developing pancreatic cancer after 50 years of age.